Open Beta
TREN
MetriLume
TREN

US marketsANIP

SEC-sourced researchBeta

ANIP

ANI PHARMACEUTICALS INC

Company comparison ↗

Data passport

CIK
0001023024
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 30, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 486,816,000.0000 USD; December 2024: 614,376,000.0000 USD; December 2025: 883,366,000.0000 USD883.4M USD0 USD0December 2023December 2024December 2025
ANIP · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023486,816,000.0000Feb 27, 2026
December 2024614,376,000.0000Feb 27, 2026
December 2025883,366,000.0000Feb 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025883,366,000.000078,337,000.0000185,225,000.00001,440,377,000.0000899,653,000.0000Feb 27, 2026
December 2024614,376,000.0000-18,522,000.000064,017,000.00001,284,469,000.0000855,939,000.0000Feb 27, 2026
December 2023486,816,000.000018,779,000.0000118,959,000.0000——Feb 27, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

78/100
Profitability68
Growth94
Balance sheet38
Cash generation92
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$883.37MJan 1, 2025 – Dec 31, 2025Feb 27, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$614.38MJan 1, 2024 – Dec 31, 2024Feb 27, 202610-K
Net incomeNetIncomeLoss$78.34MJan 1, 2025 – Dec 31, 2025Feb 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$185.23MJan 1, 2025 – Dec 31, 2025Feb 27, 202610-K
Total assetsAssets$1.44BDec 31, 2025Feb 27, 202610-K
Total liabilitiesLiabilities$899.65MDec 31, 2025Feb 27, 202610-K

New filings

Explore methodology ↗